… aim of this paper is to review the current state of the model-based approaches to predict
clinical pharmacokinetics and DDIs of drugs or NMEs that are substrates of hepatic transporters. …

… Clinical pharmacokinetic studies indicated that the different SLCO1B1 haplotypes correlated
with the pharmacokinetics of many statins studied, reducing hepatic uptake and efficacy …

… drug development and clinical practice. In this review, we selected some clinically important
drug transporters … pharmacokinetic, pathophysiological, and pharmacogenetic implications. …

… that the impact of hepatic BCRP on the overall pharmacokinetics of BCRP substrates cannot
… pharmacokinetics of drugs is probably much larger than at the canalicular side of liver cells. …

… hepatic transporters in pharmacokinetics and drug-drug interactions (DDIs). Special emphasis
is placed on transporters … 1B3 emerged as important hepatic drug uptake pathways, sites …

… Recent years have seen great advances in our ability to predict transporter-mediated
pharmacokinetics and drug interactions. Decision trees for determining when clinical …

… transporters involved in the pharmacokinetics of … hepatic clearance from animals to humans.
In vitro experimental systems used to evaluate the functions of membrane transporters are …

… This paper reviews the pharmacokinetic principles that govern the kinetics of uptake transporter
… for assessing hepatic drug clearance and the impact of drug−drug interactions (DDIs). …

… Several basolateral transporters are present to conduct transport of organic anions,
cations, and bile acids into the liver. In the past, our laboratory has utilized pharmacokinetic …

… the influence intestinal and hepatic drug transporters have on pharmacokinetic parameters,
… dosed drugs. This review also describes in detail the Biopharmaceutics Drug Disposition …